Orum Therapeutics rakes in $84m Series B
Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.
Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.